These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26099985)

  • 1. Immunotherapy: Combined immunotherapy--a new standard in metastatic melanoma?
    Hauschild A; Garbe C
    Nat Rev Clin Oncol; 2015 Aug; 12(8):439-40. PubMed ID: 26099985
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined immunotherapy improves survival in metastatic melanoma.
    Mayor S
    BMJ; 2015 Jun; 350():h2993. PubMed ID: 26036979
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy Combo Effective in Melanoma.
    Cancer Discov; 2015 Jul; 5(7):OF1. PubMed ID: 26069187
    [No Abstract]   [Full Text] [Related]  

  • 4. [New hope in metastatic melanoma treatment?].
    Guillot B
    Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
    [No Abstract]   [Full Text] [Related]  

  • 5. [Medical therapy of malignant melanoma].
    Mini E; Periti P
    Ann Ital Chir; 1989; 60(4):257-63. PubMed ID: 2699710
    [No Abstract]   [Full Text] [Related]  

  • 6. Dual Immunotherapies Shrink Melanomas.
    Cancer Discov; 2015 Jul; 5(7):OF9. PubMed ID: 25998399
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of nivolumab in melanoma.
    Gomes F; Serra-Bellver P; Lorigan P
    Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
    Valsecchi ME
    N Engl J Med; 2015 Sep; 373(13):1270. PubMed ID: 26398077
    [No Abstract]   [Full Text] [Related]  

  • 9. The place of PD-1 inhibitors in melanoma management.
    Bowyer S; Lorigan P
    Lancet Oncol; 2015 Aug; 16(8):873-4. PubMed ID: 26115798
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination Immunotherapy for Melanoma.
    Kaufman HL
    JAMA Oncol; 2015 Jun; 1(3):387-8. PubMed ID: 26181189
    [No Abstract]   [Full Text] [Related]  

  • 11. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
    Yamazaki N; Maeda Y
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
    [No Abstract]   [Full Text] [Related]  

  • 12. Nivolumab + ipilimumab ups melanoma response.
    Cancer Discov; 2015 Jun; 5(6):OF2. PubMed ID: 25898833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma: CheckMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab.
    Errico A
    Nat Rev Clin Oncol; 2015 Aug; 12(8):435. PubMed ID: 26099982
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.
    Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; Prat A; Arance A
    Clin Transl Oncol; 2017 Jan; 19(1):119-124. PubMed ID: 27147251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ipilimub for advanced melanoma].
    Kiyohara Y
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):439-42. PubMed ID: 26020985
    [No Abstract]   [Full Text] [Related]  

  • 16. NICE approves immunotherapy combination for advanced melanoma.
    Wise J
    BMJ; 2016 Jun; 353():i3421. PubMed ID: 27317590
    [No Abstract]   [Full Text] [Related]  

  • 17. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
    Melnikova VO; Bar-Eli M
    Pigment Cell Res; 2006 Oct; 19(5):395-405. PubMed ID: 16965268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective.
    Goldstein DA; Zeichner SB
    Am J Manag Care; 2015 Sep; 21(10 Suppl):S234-41. PubMed ID: 26619297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
    Hersey P; Sosman J; O'Day S; Richards J; Bedikian A; Gonzalez R; Sharfman W; Weber R; Logan T; Buzoianu M; Hammershaimb L; Kirkwood JM;
    Cancer; 2010 Mar; 116(6):1526-34. PubMed ID: 20108344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.